guest ::
| Home > Publications database > Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. > print |
| Home > Publications database > Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. > print |
| 001 | 147736 | ||
| 005 | 20240229112656.0 | ||
| 024 | 7 | _ | |a 10.1093/noajnl/vdz027 |2 doi |
| 024 | 7 | _ | |a pmid:31763624 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6860004 |2 pmc |
| 024 | 7 | _ | |a altmetric:71194246 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-02713 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Treisman, Daniel M |b 0 |
| 245 | _ | _ | |a Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. |
| 260 | _ | _ | |a Oxford |c 2019 |b Oxford University Press |
| 264 | _ | 1 | |3 online |2 Crossref |b Oxford University Press (OUP) |c 2019-09-23 |
| 264 | _ | 1 | |3 print |2 Crossref |b Oxford University Press (OUP) |c 2019-05-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Oxford University Press (OUP) |c 2019-05-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1692363840_16382 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Neuro-Oncology Advances () = 2632-2498 (import from CrossRef, PubMed, )E-ISSN(s): 2632-2498 |
| 520 | _ | _ | |a High-intensity therapy effectively treats most TP53 wild-type (TP53-WT) Sonic Hedgehog-subgroup medulloblastomas (SHH-MBs), but often cause long-term deleterious neurotoxicities in children. Recent clinical trials investigating reduction/de-escalation of therapy for TP53-WT SHH-MBs caused poor overall survival. Here, we investigated whether reduced levels of p53-pathway activation by low-intensity therapy potentially contribute to diminished therapeutic efficacy.Using mouse SHH-MB models with different p53 activities, we investigated therapeutic efficacy by activating p53-mediated cell-cycle arrest versus p53-mediated apoptosis on radiation-induced recurrence.Upon radiation treatment, p53WT-mediated apoptosis was sufficient to eliminate all SHH-MB cells, including Sox2+ cells. The same treatment eliminated most Sox2- bulk tumor cells in SHH-MBs harboring p53R172P, an apoptosis-defective allele with cell-cycle arrest activity, via inducing robust neuronal differentiation. Rare quiescent Sox2+ cells survived radiation-enhanced p53R172P activation and entered a proliferative state, regenerating tumors. Transcriptomes of Sox2+ cells resembled quiescent Nestin-expressing progenitors in the developing cerebellum, expressing Olig2 known to suppress p53 and p21 expression. Importantly, high SOX2 expression is associated with poor survival of all four SHH-MB subgroups, independent of TP53 mutational status.Quiescent Sox2+ cells are efficiently eliminated by p53-mediated apoptosis, but not cell-cycle arrest and differentiation. Their survival contributes to tumor recurrence due to insufficient p53-pathway activation. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 542 | _ | _ | |i 2019-09-23 |2 Crossref |u http://creativecommons.org/licenses/by/4.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Li, Yinghua |b 1 |
| 700 | 1 | _ | |a Pierce, Brianna R |b 2 |
| 700 | 1 | _ | |a Li, Chaoyang |b 3 |
| 700 | 1 | _ | |a Chervenak, Andrew P |b 4 |
| 700 | 1 | _ | |a Tomasek, Gerald J |b 5 |
| 700 | 1 | _ | |a Lozano, Guillermina |b 6 |
| 700 | 1 | _ | |a Zheng, Xiaoyan |b 7 |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 8 |u dkfz |
| 700 | 1 | _ | |a Zhu, Yuan |b 9 |
| 773 | 1 | 8 | |a 10.1093/noajnl/vdz027 |b Oxford University Press (OUP) |d 2019-05-01 |n 1 |3 journal-article |2 Crossref |t Neuro-Oncology Advances |v 1 |y 2019 |x 2632-2498 |
| 773 | _ | _ | |a 10.1093/noajnl/vdz027 |g Vol. 1, no. 1, p. vdz027 |0 PERI:(DE-600)3009682-0 |n 1 |p vdz027 |t Neuro-oncology advances |v 1 |y 2019 |x 2632-2498 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:147736 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-09-23T13:25:59Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0112 |2 StatID |b Emerging Sources Citation Index |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-12 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1016/j.ccr.2014.02.004 |9 -- missing cx lookup -- |1 Kool |p 393 - |2 Crossref |t Cancer Cell. |v 25 |y 2014 |
| 999 | C | 5 | |a 10.1016/j.ccell.2017.05.005 |9 -- missing cx lookup -- |1 Cavalli |p 737 - |2 Crossref |t Cancer Cell |v 31 |y 2017 |
| 999 | C | 5 | |a 10.1038/s41572-019-0063-6 |9 -- missing cx lookup -- |1 Northcott |p 11 - |2 Crossref |t Nat Rev Dis Primers. |v 5 |y 2019 |
| 999 | C | 5 | |a 10.1016/j.ccr.2008.07.005 |9 -- missing cx lookup -- |1 Schüller |p 123 - |2 Crossref |t Cancer Cell. |v 14 |y 2008 |
| 999 | C | 5 | |a 10.1016/j.ccr.2008.07.003 |9 -- missing cx lookup -- |1 Yang |p 135 - |2 Crossref |t Cancer Cell. |v 14 |y 2008 |
| 999 | C | 5 | |a 10.1038/s41586-019-1434-6 |9 -- missing cx lookup -- |1 Hovestadt |p 74 - |2 Crossref |t Nature. |v 572 |y 2019 |
| 999 | C | 5 | |a 10.1038/s41586-019-1158-7 |9 -- missing cx lookup -- |1 Vladoiu |p 67 - |2 Crossref |t Nature. |v 572 |y 2019 |
| 999 | C | 5 | |a 10.1007/s12311-015-0724-2 |9 -- missing cx lookup -- |1 Leto |p 789 - |2 Crossref |t Cerebellum. |v 15 |y 2016 |
| 999 | C | 5 | |a 10.1016/j.molmed.2016.03.006 |9 -- missing cx lookup -- |1 Barthelery |p 404 - |2 Crossref |t Trends Mol Med. |v 22 |y 2016 |
| 999 | C | 5 | |a 10.1007/s00401-016-1569-6 |9 -- missing cx lookup -- |1 Ramaswamy |p 821 - |2 Crossref |t Acta Neuropathol. |v 131 |y 2016 |
| 999 | C | 5 | |a 10.1200/JCO.2012.48.5052 |9 -- missing cx lookup -- |1 Zhukova |p 2927 - |2 Crossref |t J Clin Oncol. |v 31 |y 2013 |
| 999 | C | 5 | |a 10.1002/pbc.26042 |9 -- missing cx lookup -- |1 Lafay-Cousin |p 1527 - |2 Crossref |t Pediatr Blood Cancer |v 63 |y 2016 |
| 999 | C | 5 | |a 10.1002/cncr.25856 |9 -- missing cx lookup -- |1 Leary |p 3262 - |2 Crossref |t Cancer |v 117 |y 2011 |
| 999 | C | 5 | |a 10.1016/S1470-2045(18)30204-3 |9 -- missing cx lookup -- |1 Robinson |p 768 - |2 Crossref |t Lancet Oncol |v 19 |y 2018 |
| 999 | C | 5 | |a 10.1016/j.cell.2017.08.028 |9 -- missing cx lookup -- |1 Kastenhuber |p 1062 - |2 Crossref |t Cell. |v 170 |y 2017 |
| 999 | C | 5 | |a 10.1158/0008-5472.CAN-15-0025 |9 -- missing cx lookup -- |1 Crowther |p 3211 - |2 Crossref |t Cancer Res |v 76 |y 2016 |
| 999 | C | 5 | |a 10.1101/gad.1627008 |9 -- missing cx lookup -- |1 Hambardzumyan |p 436 - |2 Crossref |t Genes Dev. |v 22 |y 2008 |
| 999 | C | 5 | |a 10.1038/nrc992 |9 -- missing cx lookup -- |1 Gudkov |p 117 - |2 Crossref |t Nat Rev Cancer. |v 3 |y 2003 |
| 999 | C | 5 | |a 10.1016/j.celrep.2016.02.061 |9 -- missing cx lookup -- |1 Tamayo-Orrego |p 2925 - |2 Crossref |t Cell Rep |v 14 |y 2016 |
| 999 | C | 5 | |a 10.1158/0008-5472.CAN-13-0238 |9 -- missing cx lookup -- |1 Ahlfeld |p 3796 - |2 Crossref |t Cancer Res. |v 73 |y 2013 |
| 999 | C | 5 | |a 10.1016/j.ccr.2014.05.005 |9 -- missing cx lookup -- |1 Vanner |p 33 - |2 Crossref |t Cancer Cell. |v 26 |y 2014 |
| 999 | C | 5 | |a 10.1016/j.ccr.2009.04.001 |9 -- missing cx lookup -- |1 Wang |p 514 - |2 Crossref |t Cancer Cell. |v 15 |y 2009 |
| 999 | C | 5 | |a 10.1016/j.celrep.2018.06.050 |9 -- missing cx lookup -- |1 Akgul |p 463 - |2 Crossref |t Cell Reports. |v 24 |y 2018 |
| 999 | C | 5 | |a 10.1038/ng1282 |9 -- missing cx lookup -- |1 Liu |p 63 - |2 Crossref |t Nat Genet |v 36 |y 2004 |
| 999 | C | 5 | |1 Wetmore |y 2001 |2 Crossref |o Wetmore 2001 |
| 999 | C | 5 | |1 Louis |y 2007 |2 Crossref |t WHO Classification of Tumors of the Central Nervous System |o Louis WHO Classification of Tumors of the Central Nervous System 2007 |
| 999 | C | 5 | |a 10.1371/journal.pone.0003088 |9 -- missing cx lookup -- |1 Kool |p e3088 - |2 Crossref |t Plos One. |v 3 |y 2008 |
| 999 | C | 5 | |a 10.1038/nature11213 |9 -- missing cx lookup -- |1 Robinson |p 43 - |2 Crossref |t Nature. |v 488 |y 2012 |
| 999 | C | 5 | |a 10.1038/nn.3553 |9 -- missing cx lookup -- |1 Li |p 1737 - |2 Crossref |t Nat Neurosci. |v 16 |y 2013 |
| 999 | C | 5 | |a 10.1038/nn.4621 |9 -- missing cx lookup -- |1 Wojcinski |p 1361 - |2 Crossref |t Nat Neurosci |v 20 |y 2017 |
| 999 | C | 5 | |a 10.1016/j.neuron.2007.01.009 |9 -- missing cx lookup -- |1 Ligon |p 503 - |2 Crossref |t Neuron. |v 53 |y 2007 |
| 999 | C | 5 | |a 10.1016/j.ccr.2011.01.035 |9 -- missing cx lookup -- |1 Mehta |p 359 - |2 Crossref |t Cancer Cell |v 19 |y 2011 |
| 999 | C | 5 | |a 10.1101/cshperspect.a026211 |1 Wasylishen |9 -- missing cx lookup -- |2 Crossref |t Cold Spring Harb Perspect Med |v 6 |y 2016 |
| 999 | C | 5 | |a 10.1038/sj.onc.1205973 |9 -- missing cx lookup -- |1 Pazzaglia |p 7580 - |2 Crossref |t Oncogene. |v 21 |y 2002 |
| 999 | C | 5 | |a 10.1038/sj.onc.1209032 |9 -- missing cx lookup -- |1 Pazzaglia |p 1165 - |2 Crossref |t Oncogene. |v 25 |y 2006 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|